Synthesis of a substance P antagonist with a somatostatin Scaffold: Factors affecting agonism/antagonism at GPCRs and the role of pseudosymmetry [4]

Journal of Medicinal Chemistry

Volumn 43, Issue 21, 2000, Pages 3827-3831

  Liu, J ^a   Underwood, D J ^a   Cascieri, M A ^a   Rohrer, S P ^a   Cantin, L D ^a   Chicchi, G ^a   Smith III, A B ^a   Hirschmann, R ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLO(PROLYLPHENYLALANYL DEXTRO TRYPTOPHYLLYSYLTHREONYLPHENYLALANYL); NEUROKININ 1 RECEPTOR; SOMATOSTATIN 14; SOMATOSTATIN DERIVATIVE; SUBSTANCE P ANTAGONIST;

DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; LETTER;

ANIMALS; CHO CELLS; COS CELLS; CRICETINAE; GLUCOSIDES; HUMANS; MEMBRANE PROTEINS; MOLECULAR MIMICRY; RECEPTORS, NEUROKININ-1; RECEPTORS, SOMATOSTATIN; SOMATOSTATIN; SUBSTANCE P;

EID: 0034687226     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm000316h     Document Type: Letter

References (50)

1. Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituary growth hormone
2. Somatostatin. Total solid-phase synthesis
3. Peptide analogue design based on conformation
4. A potent cyclic hexapeptide analogue of somatostatin
5. 2]-dihydrosomatostatin analogues
6. Conformationally restricted bicyclic analogues of somatostatin
7. A super active cyclic hexapeptide analogue of somatostatin
8. De novo design and synthesis of somatostatin non-peptide peptidomimetics utilizing β-D-glucose as a novel scaffolding
9. Modulation of receptor and receptor subtype affinities using diastereomeric and enantiomeric monosaccharide scaffolds as a means to structural and biological diversity. A new route to ether synthesis
10. Nonpeptidal peptidomimetics with β-D-glucose scaffolding. A partial somatostatin agonist bearing a close structural relationship to a potent, selective substance p antagonist
11. Opioid peptides: Simultaneous delta agonism and mu antagonism in somatostatin analogues
12. Molecular charaterization of a common binding site for small molecules within the transmembrane domain of G-protein coupled receptors
13. Methods for drug discovery: Development of potent, selective, orally effective cholecystokinin antagonists
14. Synthesis of potent cyclic hexapeptide NK-1 antagonists. Use of a minilibrary in transforming a peptidal somatostatin receptor ligand into an NK-1 receptor ligand via a polyvalent peptidomimetic
15. Characterization of the binding of a potent, selective radio-iodinated antagonist to the human neurokinin-1 receptor
16. Structure-activity relationships of a synthetic pentapeptide that specifically releases growth hormone in vitro
17. Structure and function of G protein-coupled receptors
18. Identification of residues involved in ligand binding to the neurokinin-2 receptor
19. Synthesis and biological activities of potent peptidomimetics selective for somatostatin receptor subtype-2
20. Design of novel cyclic hexapeptide somatostatin analogues from a model of the bioactive conformation
21. A combinatorial approach towards the discovery of non-peptide, subtype-selective somatostatin receptor ligands
22. 2) agonists
23. 2-adrenoceptor
24. The two-state model of receptor activation
25. Precoupling of Gi/Go-linked receptors and its allosteric regulation by monovalent cations
26. Getting it together: Signal transduction in G-protein coupled receptors by association of receptor domains
27. Two-site binding of C5a by its receptor: An alternative binding paradigm for G protein-coupled receptors
28. Purification of opioid receptor in the presence of sodium ions
29. Identification and charaterization of novel somatostatin antagonists
30. Potent antagonists of somatostatin: Synthesis and biology
31. Highly potent cyclic disulfide antagonists of somatostatin
32. A linear hexapeptide somatostatin antagonist blocks somatostatin activity in vitro and influences growth hormone release in rats
33. Activity of spantide I and II at various tachykinin receptors and NK-2 tachykinin receptor subtypes
34. Potent and highly selective neurokinin antagonists
35. Membrane-induced secondary structures of neuropeptides: A comparison of the solution conformations adopted by agonists and antagonists of the mammalian tachykinin NK1 receptor
36. On the low energy solution conformation of somatostatin
37. Evidence for a common molecular mode of action for chemically distinct nonpeptide antagonists at the neurokinin-1 (substance P) receptor
38. Functional mapping of the ligand binding sites of G-protein coupled receptors
39. Two related neurokinin-1 receptor antagonists have overlapping but different binding sites
40. Interaction of glutamine-165 in the fourth transmembrane segment of the human neurokinin-1 receptor with quinuclidine antagonists
41. Identification of critical functional groups within binding pockets of G-protein-coupled receptors
42. Tachykinin non-peptide antagonists: Binding domain and molecular mode of action
43. Structure of the Mdm2 oncoprotein bound to the p53 tumor suppressor transactivation domain